Update on Advanced Proteome Therapeutics' Anticancer Program
22 May 2014 - 11:00PM
Marketwired
Update on Advanced Proteome Therapeutics' Anticancer Program
VANCOUVER, BRITISH COLUMBIA--(Marketwired - May 22, 2014) -
Advanced Proteome Therapeutics Corporation ("APC" or the "Company")
(TSX-VENTURE:APC) reports that the recent positive results in the
Company's anticancer program have driven an increase in the
Company's activities, in order to more rapidly capitalize on our
findings and advance our innovative program to generate clinical
interest and deal-making. We are building on recent results with
collaborators in which we have demonstrated that modifications of
our protein delivery system substantially increase antitumor
activity and retard tumor growth in animals.
The Company is pursuing R&D that is advancing on three
fronts to maximize possibilities for successful drug development
and deal making. First, conjugates of its protein delivery system
bearing chemotherapeutic drugs have been prepared and are currently
being tested in animal models. Second, the antitumor activity of
the protein, which itself has been shown to retard tumor growth,
has been substantially increased (as reported for Series 1) by
modifications that enhance affinity to the target biomarker on
cancer cells, and thus retard tumor growth in animals. The
encouraging affinity patterns to tumor cells that have been
observed with members of Series I, have also been observed with
Series 2, and series 3 is being readied for testing. Thirdly,
besides our robust chemical modification capability, we have added
recombinant DNA techniques to generate mutant fusion proteins that
are now being produced and chemically modified. Such recombinantly
generated proteins have been designed to allow for application of
the full array of APC enhancements to the protein delivery system
and to further strengthen our proprietary patent estate, which has
been the subject of recent filings.
Further, the Company is involved in expanding access to
equipment and instrumentation to cover the current needs of Company
scientists who have been vigorously engaged in scaling up
quantities of materials for multi-dose animal testing by our
collaborators, in addition to their normal R&D activities. To
more rapidly advance the program and provide increased support to
our in-house efforts, contracts with our academic collaborators
have been extended and will be announced shortly.
Besides ongoing work with fibrosarcoma cancer cell lines,
testing in animal models in breast cancer have begun and an ovarian
cancer cell line has been acquired, and still other possibilities
are being considered. During the next several weeks results from
biological testing are expected that will provide an indication as
to which of our candidate molecules are appropriate for treating a
specific cancer type.
Alexander Krantz, President and Chief Executive Officer of APC,
said "The Company while thoroughly engaged in anti-cancer research,
an immensely critical area of unmet needs, is focused on cancer
immunotherapy, arguably the most exciting and promising area in
current cancer research. From our innovative program, we have
generated an ever increasing number of drug candidates, many of
which are being tested to evaluate their potential as monotherapies
and in combination immunotherapy. Advanced Proteome Therapeutics
should be well-positioned to positively impact this vital area of
therapeutic need which provides the optimal balance of costs and
benefits."
About APC
APC has been applying its Foundation Trinity™ Technology to
proteins targeted for the treatment of cancers. Advanced targeted
therapies are designed to attack primarily cancer cells and are
expected to dominate the anti-cancer therapeutics' market in the
near future. The Company's goals are not only to employ therapy
targeted for tumor cells, but also to deliver combination therapy
in a single, pure therapeutic agent. To achieve this end, it has
been the Company's intention to utilize a unique protein (and
related systems), not only as a delivery vehicle to tumor cells,
but also as a scaffold upon which to attach each anti-cancer entity
to its own specific site on the protein surface - both key to
efficient manufacturing and product development. The protein
vehicle has emerged as a potential immunotherapeutic as it is
implicated in activating the immune system to attack and help clear
tumor cells. Immunotherapy is perhaps the most powerful current
approach to cancer, and one of great commercial interest to the
pharmaceutical industry.
ON BEHALF OF THE BOARD
Alexander (Allen) Krantz, President and Chief Executive
Officer
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release. The forward-looking statements contained
in this news release involve risks and uncertainties, and are
subject to change based on various important factors including
timely development and acceptance of new products, gaining product
approval, successful entry into new markets, changes in financing
conditions, and changes in FDA regulations.
Advanced Proteome Therapeutics Corporation(617)
638-0340www.advancedproteome.com
Advanced Proteome Therap... (TSXV:APC)
Historical Stock Chart
From Oct 2024 to Nov 2024
Advanced Proteome Therap... (TSXV:APC)
Historical Stock Chart
From Nov 2023 to Nov 2024